Kyntra Bio Inc Dossier - Source-backed chat

Kyntra Bio Inc

KYNBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.02

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.50Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $26.3M

Enterprise Value $50.7M

Shares Outstanding 4.1M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Kyntra Bio Inc. (formerly FibroGen, Inc.) has successfully transitioned into a streamlined, clinical-stage oncology and rare disease biopharmaceutical company. Following the strategic sale of FibroGen China and the payoff of its senior secured term loan in 2025, the company has extended its cash runway into 2028. The investment thesis centers on the clinical advancement of its lead assets: FG-3246, a first-in-class CD46-targeting antibody-drug conjugate (ADC) currently in Phase 2 development for metastatic castration-resistant prostate cancer (mCRPC), and roxadustat, which is poised to enter a pivotal Phase 3 trial for lower-risk myelodysplastic syndromes (LR-MDS) in the second half of 2026. With a significantly reduced cost structure and a market capitalization of approximately $27M to $31M, positive clinical readouts present substantial asymmetric upside.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$35.00

Mean target$39.00

High · most bullish analyst$43.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$35.0015%

The interim analysis of FG-3246 in Q4 2026 reveals safety concerns (such as severe neutropenia or cumulative peripheral neuropathy) or insufficient monotherapy efficacy, limiting its clinical path. Additionally, the initiation of the Phase 3 roxadustat trial in LR-MDS is delayed past 2026 due to regulatory hurdles or partnership challenges, accelerating cash burn and forcing highly dilutive equity financing.

Base CaseCentral scenario

$39.0060%

Matches the consensus mean

FG-3246's Phase 2 monotherapy interim analysis in Q4 2026 shows competitive efficacy and manageable safety, in line with the positive Phase 1b/2 combination data presented at ASCO GU 2026. The pivotal Phase 3 trial of roxadustat in LR-MDS begins in late 2026 following FDA protocol finalization. The company's cash runway remains sufficient to fund operations into 2028, allowing steady pipeline progression without immediate dilutive financing.

Bull CaseUpside scenario

$43.0025%

The Phase 2 monotherapy trial of FG-3246 delivers outstanding progression-free survival (PFS) and safety data in Q4 2026, establishing it as a best-in-class ADC for mCRPC. Concurrently, the pivotal Phase 3 trial of roxadustat in LR-MDS initiates smoothly in 2H 2026 with strong enrollment, attracting a major pharmaceutical partner for co-development and commercialization in the US, Canada, and Mexico, which triggers significant milestone payments and non-dilutive funding.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Extended cash runway into 2028 following the $220M sale of FibroGen China and debt payoff, providing financial stability for clinical execution.
First-in-class CD46-targeting ADC (FG-3246) showing strong preliminary efficacy, including a median rPFS of 10.1 months in patients with one prior ARPI when combined with enzalutamide.
Phase 3-ready asset (roxadustat) for LR-MDS with Orphan Drug Designation, targeting a high unmet need population with a validated oral mechanism of action.

Key Investment Risks

High clinical development risk typical of oncology and rare disease therapeutics, with potential for trial delays or failures.
History of late-stage clinical setbacks under the former FibroGen corporate identity, which may weigh on investor sentiment until clinical milestones are met.
Rapid cash burn rate despite the extended runway, which will eventually require additional capital or strategic partnerships to complete Phase 3 development.

Thesis Invalidation Triggers

Failure of FG-3246 to meet efficacy thresholds or acceptable safety profiles in the Q4 2026 Phase 2 interim analysis.
Inability to initiate the pivotal Phase 3 roxadustat trial in LR-MDS by the end of 2026.
Significant downward revisions in cash runway projections or unexpected regulatory roadblocks from the FDA.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.